Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Johnson & Johnson (NYSE:JNJ)

117.27
Delayed Data
As of 4:00pm ET
 -2.12 / -1.78%
Today’s Change
91.76
Today|||52-Week Range
126.07
+14.16%
Year-to-Date
Valuation Is a Measurement of Soundness and Not the Primary Total Return Producer: Pa...
5:08pm / GuruFocus News - Paid Partner Content
Gilead Sciences Inc.'s Biggest Win in 2016 So Far
Sep 22 / MotleyFool.com - Paid Partner Content
Troubles for Deutsche Bank, Wells Fargo Drag Down Wall Street
4:09pm / TheStreet.com - Paid Partner Content
Hate Risk? You'll Love These 3 Stocks
Sep 22 / MotleyFool.com - Paid Partner Content
Intra-Cellular Reports Poor Phase III Schizophrenia Data
12:07pm / Zacks.com - Paid Partner Content
Better Buy: Procter & Gamble vs. Johnson & Johnson
Sep 21 / MotleyFool.com - Paid Partner Content
How Oncology Could Move the Needle for Johnson & Johnson's Stock
9:15am / MotleyFool.com - Paid Partner Content
Move Over, Intuitive Surgical, Here's How Johnson & Johnson and Google Plan to Build ...
Sep 21 / MotleyFool.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. AbbVie
Sep 28 / MotleyFool.com - Paid Partner Content
Big pharma targets drug-resistant superbugs
Sep 20 / FT.com - Paid Partner Content
Ratings on the Largest Stocks - Buy, Neutral or Avoid
Sep 28 / GuruFocus News - Paid Partner Content
Johnson & Johnson's Smart (Yet Surprising) Acquisition
Sep 20 / MotleyFool.com - Paid Partner Content
3 Stocks With Better Dividends Than Procter & Gamble
Sep 28 / MotleyFool.com - Paid Partner Content
Zacks.com featured highlights: Baxter International, AO Smith, Johnson & Johnson, BWX...
Sep 20 / Zacks.com - Paid Partner Content
Ariel Funds Comments on Johnson & Johnson
Sep 28 / GuruFocus News - Paid Partner Content
Pfizer (PFE) Breast Cancer Drug Ibrance Wins CHMP Backing
Sep 20 / Zacks.com - Paid Partner Content
Heartening News for J&J: Americans Feel 'Great' About the Economy
Sep 28 / TheStreet.com - Paid Partner Content
Apple Didn't Waste Billions on Its Buyback Program, but These Companies Did
Sep 19 / MotleyFool.com - Paid Partner Content
John Rogers' Ariel Global Fund 2nd Quarter Commentary
Sep 28 / GuruFocus News - Paid Partner Content
Stock Market News for September 19, 2016
Sep 19 / Zacks.com - Paid Partner Content
Why Johnson & Johnson's New Wearable for Diabetics Should Be a Home Run
Sep 28 / MotleyFool.com - Paid Partner Content
AstraZeneca Diabetes Drug Combination Positive in Phase III
Sep 19 / Zacks.com - Paid Partner Content
What Gives With Biosimilars?
Sep 27 / MotleyFool.com - Paid Partner Content
5 Efficient Stocks to Ensure High Yields
Sep 19 / Zacks.com - Paid Partner Content
3 Top Stocks for Low-Risk Investors to Buy Now
Sep 27 / MotleyFool.com - Paid Partner Content
J&J (JNJ) to Buy Abbott's Vision Care Unit for $4.3 Billion
Sep 19 / Zacks.com - Paid Partner Content
AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica
Sep 27 / Zacks.com - Paid Partner Content
When a benchmark can be an illusion
Sep 19 / FT.com - Paid Partner Content
The 3 Best-Run Companies in the Healthcare Sector
Sep 27 / MotleyFool.com - Paid Partner Content
Hate Checking Your Portfolio? Try These 2 Stocks
Sep 18 / MotleyFool.com - Paid Partner Content
These are the best companies for working moms
Sep 27 / CNNMoney.com
Is This New Market the Biggest Investment Idea of the Decade?
Sep 17 / MotleyFool.com - Paid Partner Content
Wall Street Sells Off on Worries Over Clinton-Trump Showdown
Sep 26 / TheStreet.com - Paid Partner Content
The 3 Best Long-Term Dividend Stocks to Buy Now
Sep 16 / MotleyFool.com - Paid Partner Content
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
Sep 26 / TheStreet.com - Paid Partner Content
Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III
Sep 16 / Zacks.com - Paid Partner Content
J&J Finally Returning to Its Roots in Diversity?
Sep 26 / GuruFocus News - Paid Partner Content
Sarepta Shares Soar on News of Key Drug Critic FDA Exit
Sep 15 / Zacks.com - Paid Partner Content
Achillion, J&J HCV Triple Combination Drug Data Presented
Sep 26 / Zacks.com - Paid Partner Content
Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (revised)
Sep 15 / Zacks.com - Paid Partner Content
Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.
Sep 26 / Zacks.com - Paid Partner Content
FDA Panel Suggests Removing Warning from Pfizer's Chantix
Sep 15 / Zacks.com - Paid Partner Content
Ignore Procter & Gamble: Here Are 3 Better Stocks
Sep 25 / MotleyFool.com - Paid Partner Content
Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Sep 15 / Zacks.com - Paid Partner Content
Biotech Stocks Under $5: 2 to Buy, 1 to Avoid
Sep 24 / MotleyFool.com - Paid Partner Content
What the 'Nifty Fifty' can tell us about bond proxies
Sep 14 / FT.com - Paid Partner Content
The 5 Most-Sold Stocks of All US Investment Funds
Sep 23 / GuruFocus News - Paid Partner Content
Whistleblower lands a $22 million payday from SEC for tips about Monsanto fraud
Aug 31 / CNNMoney.com
John Paulson Trims Synergy
Sep 23 / GuruFocus News - Paid Partner Content